Akero Therapeutics, Inc. (AKRO)

Akero Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies to treat serious metabolic diseases, such as non-alcoholic steatohepatitis (NASH). The company was founded in 2017 and is headquartered in South San Francisco, California. Led by its CEO, Andrew Cheng, Akero aims to address these challenging health conditions by developing medicines that can significantly improve patient outcomes. Although specific revenue figures can vary, the company is primarily focused on advancing its product pipeline rather than generating immediate profitability. Akero is dedicated to leveraging deep scientific expertise to tackle metabolic diseases through a patient-centric approach.